Company: LGNZZ
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000886163-25-000051
Chunk: 67

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-08-08
Form: 10-Q
Item: Item 8
Chunk 67
---
144 Rylaze 2,864 3,232 5,983 6,184 Filspari6,578 2,424 11,879 4,196 Vaxneuvance2,643 1,109 3,928 2,496 Other5,433 2,004 9,420 4,180 Revenue from intangible royalty assets30,084 22,603 51,671 40,960 Qarziba5,885 — 11,327 — Other428 559 888 1,297 Income from financial royalty assets6,313 559 12,215 1,297 Total royalties36,397 23,162 63,886 42,257 Captisol8,287 7,500 21,747 16,712 Contract revenue and other incomeMilestone and other1,926 10,869 6,310 11,596 Other income1,017 — 1,017 1,944 Contract revenue and other income2,943 10,869 7,327 13,540 Total$47,627 $41,531 $92,960 $72,509 Short-term InvestmentsOur short-term investments consist of the following at June 30, 2025 and December 31, 2024 (in thousands):June 30, 2025Amortized costGross unrealized gainsGross unrealized lossesEstimated fair value     U.S. Treasuries$64,585 $1 $(16)$64,570      Commercial paper54,436 3 (29)54,410      Corporate notes/bonds17,138 13 (11)17,140      Corporate equity securities7,828 2,077 (1,915)7,990      Certificates of Deposit6,741 1 (1)6,741 $150,728 $2,095 $(1,972)150,851       Viking common stock26,500 Total short-term investments$177,351 December 31, 2024     U.S. Treasuries$78,442 $19 $(13)$78,448      Commercial paper23,483 5 (6)23,482      Certificates of Deposit22